JP2019525923A5 - - Google Patents

Info

Publication number

JP2019525923A5

JP2019525923A5 JP2019503485A JP2019503485A JP2019525923A5 JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5 JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

subject

delivered

eye

des

Prior art date

2017-07-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 20
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims 9
• 206010013774 Dry eye Diseases 0.000 claims 9
• 239000012634 fragment Substances 0.000 claims 7
• 239000000203 mixture Substances 0.000 claims 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 239000003795 chemical substances by application Substances 0.000 claims 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims 6
• 206010052143 Ocular discomfort Diseases 0.000 claims 4
• 239000000607 artificial tear Substances 0.000 claims 3
• 239000000499 gel Substances 0.000 claims 2
• 239000000243 solution Substances 0.000 claims 2
• UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims 1
• 102100035000 Thymosin beta-4 Human genes 0.000 claims 1
• 230000002411 adverse Effects 0.000 claims 1
• 239000006071 cream Substances 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003889 eye drop Substances 0.000 claims 1
• 229940012356 eye drops Drugs 0.000 claims 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
• 239000007788 liquid Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002674 ointment Substances 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 239000002904 solvent Substances 0.000 claims 1
• 238000010186 staining Methods 0.000 claims 1
• 239000000725 suspension Substances 0.000 claims 1
• 108010079996 thymosin beta(4) Proteins 0.000 claims 1